🔗 Share this article

As the United States continues making sweeping changes to its vaccination guidelines, one figure appears somewhat surprisingly: Dr. Tracy Beth Høeg, a Danish American physician and public health researcher who rose to prominence by casting doubt on coronavirus vaccinations during the pandemic and has focused upon alleged fatalities following Covid immunization in her short position at the FDA.

Planned Overhauls to Pediatric Vaccine Schedule

Health officials were set to reveal major changes to the pediatric vaccine schedule in December, bringing the US with the Danish vaccine program, according to reports – a significant shift that would place the US out of alignment with a large portion of the international standard with insufficient data for improved outcomes. The announcement has been pushed back until the new year.

In place of the director of the vaccine center, Dr. Høeg is set to speak at the meeting. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth person to run the center this year.

A Shift at the FDA

The acting appointment could signify a strengthened alliance between the pharmaceutical and vaccine divisions as Dr. Høeg and Dr. Prasad solidify control at the regulatory agency – and it suggests a greater focus upon dismantling already-approved vaccines at the FDA.

The new acting director has frequently advocated for halting some childhood immunization guidelines in the US to become more in line with Denmark, a society with comprehensive healthcare and a citizenry about the population of the state of Wisconsin.

To date statements, she has persisted in emphasizing on vaccination policy – traditionally the responsibility of Prasad, director of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Concerns Over Qualifications

Høeg has no obvious experience in pharmaceutical research, oversight or management, which has been customary for former directors of the CBER. She has been employed at the FDA as a top consultant to the FDA chief and the vaccine center since earlier this year.

“She doesn’t seem to have the requisite experience” for running the drug-regulation department, remarked Dr. Jonathan Howard. “She’s never run a scientific study. She is not versed in leading a major agency. She has no expertise in drug approvals.”

Former heads of the center would “be deeply familiar with laws and regulations and the underlying principles of medication creation”, said a former acting FDA commissioner. “Clearly, she has not acquired the kind of background that prior appointees who headed the center have had.”

This division has an enormous workload at the agency, the former commissioner emphasized.

“Everybody just focuses on the new drug program, but the generic drug division approves numerous off-brand pharmaceuticals. There’s a biosimilars division, OTC medication office and so forth, and every single one need to be managed,” Woodcock said. “The area you overlook, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a major leadership element to the position, which supervises over 5,000 employees. “It is a enormous administrative position, if you execute it properly,” Woodcock added.

Agency Reaction and Disputed Programs

When asked about inquiries about Høeg’s credentials and whether this appointment signifies greater collaboration among agency officials on immunizations, a press secretary said that the “questions stem from flawed assumptions”.

“Her experience is consistent with the duties of her role,” the official said, citing the time Dr. Høeg spent counseling the agency head on “pharmaceutical safety and oversight research, including computational safety modeling and immunization monitoring”.

As acting director, Høeg inherits the commissioner’s recently launched fast-track approval initiative, a contentious one-day medication authorization process that allegedly concerned her predecessors. “By what process are these medications being picked for this expedited pathway? Who makes the calls?” Dr. Howard questioned. “There is a lot of confidentiality occurring at the regulatory body right now.”

Broadly speaking, he stated, “the FDA appears to be shifting towards less stringent regulations of all drugs, with the exception of vaccines.”

Public Track Record on Vaccines

Regarding vaccines, Høeg has a more documented, if problematic, history, critics observe. She published a study using non-validated public submissions to determine the frequency of heart inflammation after COVID-19 immunization. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have modified findings to imply Covid vaccinations are more dangerous than they are.

Included in her “desired changes” for the incoming government encompassed changing guidelines for new vaccines and ending “unnecessary” vaccines, she said after the election on a audio program. At the FDA, Høeg has according to sources suggested barring adolescent males from receiving COVID-19 vaccinations.

“She is an complete true believer who starts off with her conclusions and reverse-engineers to retrofit the data in a very deceptive, fraudulent way,” Howard argued.

Taking Control and a “Push for Payback”

Dr. Høeg became part of other contrarians, {like|